MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT
申请人:Arena Pharmaceuticals, Inc.
公开号:EP3485878A1
公开(公告)日:2019-05-22
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.
[EN] SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS<br/>[FR] SELS DE LORCASÉRINE DOTÉS D'ACIDES OPTIQUEMENT ACTIFS
申请人:ARENA PHARM INC
公开号:WO2012030938A1
公开(公告)日:2012-03-08
Salts of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine with optically active acids, and pharmaceutical compositions comprising them that are useful for, inter alia, weight management.
[EN] METHOD OF RACEMISATION OF UNDESIRED ENANTIOMERS<br/>[FR] PROCÉDÉ DE RACÉMISATION D'ÉNANTIOMÈRES INDÉSIRABLES
申请人:LEK PHARMACEUTICALS
公开号:WO2015007897A1
公开(公告)日:2015-01-22
The present invention provides a very simple, efficient and economic technology for racemisation of amines, alcohols or thioalcohols where the chiral carbon (benzylic position) is located at the β-position of the heteroatom (amino, hydroxyl or mercapto group) or even more distant therefrom. Special focus is oriented in efficient and simple racemisation of an undesired enantiomer of a chiral pharmaceutically active ingredient, preferably lorcaserin or a salt thereof, preferably the hydrochloride salt thereof. The approach according to the invention enables a use of cheaper and shorter racemic synthetic schemes not requiring expensive and toxic reagents and catalysts. Present methodology enables industrialy convenient process.